MeiraGTx Holdings PLC (NASDAQ:MGTX) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 765,900 shares, a growth of 22.7% from the August 30th total of 624,200 shares. Based on an average daily trading volume, of 185,700 shares, the days-to-cover ratio is presently 4.1 days. Currently, 3.6% of the shares of the company are short sold.
MGTX traded down $0.12 during trading on Friday, hitting $14.37. The stock had a trading volume of 173,414 shares, compared to its average volume of 225,832. The company has a debt-to-equity ratio of 0.12, a quick ratio of 5.22 and a current ratio of 5.22. The firm has a market capitalization of $487.86 million, a P/E ratio of -3.27 and a beta of 2.11. The company’s 50-day moving average price is $18.44 and its 200 day moving average price is $21.43. MeiraGTx has a twelve month low of $8.53 and a twelve month high of $30.23.
MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.47). The business had revenue of $1.98 million for the quarter. As a group, equities analysts expect that MeiraGTx will post -2.47 earnings per share for the current fiscal year.
In other news, Director Life Sciences Maste Perceptive acquired 425,531 shares of the company’s stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $23.50 per share, with a total value of $9,999,978.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 17.40% of the company’s stock.
Several large investors have recently bought and sold shares of MGTX. BlackRock Inc. grew its stake in shares of MeiraGTx by 39.6% during the 2nd quarter. BlackRock Inc. now owns 789,792 shares of the company’s stock worth $21,230,000 after purchasing an additional 224,052 shares during the period. JPMorgan Chase & Co. grew its stake in shares of MeiraGTx by 2,008.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 171,168 shares of the company’s stock worth $4,338,000 after purchasing an additional 163,050 shares during the period. Orbimed Advisors LLC grew its stake in shares of MeiraGTx by 5.1% during the 2nd quarter. Orbimed Advisors LLC now owns 2,586,951 shares of the company’s stock worth $69,537,000 after purchasing an additional 126,700 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of MeiraGTx during the 2nd quarter worth $2,023,000. Finally, Vanguard Group Inc. grew its stake in shares of MeiraGTx by 136.0% during the 2nd quarter. Vanguard Group Inc. now owns 99,197 shares of the company’s stock worth $2,667,000 after purchasing an additional 57,167 shares during the period. 37.41% of the stock is currently owned by institutional investors and hedge funds.
MeiraGTx Company Profile
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
Featured Story: What are momentum indicators and what do they show?
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.